MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
27 May 2022
Historique:
received: 14 04 2022
revised: 14 05 2022
accepted: 23 05 2022
entrez: 10 6 2022
pubmed: 11 6 2022
medline: 14 6 2022
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma and cholangiocarcinoma constitute two aggressive tumor types that originate from the epithelial lining of the excretory ducts of the pancreatobiliary tract. Given their close histomorphological resemblance, a correct diagnosis can be challenging and almost impossible without clinical information. In this study, we investigated whether mass spectrometric peptide features could be employed to distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. Three tissue microarrays of formalin-fixed and paraffin-embedded material (FFPE) comprising 41 cases of pancreatic ductal adenocarcinoma and 41 cases of cholangiocarcinoma were analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The derived peptide features and respective intensities were used to build different supervised classification algorithms: gradient boosting (GB), support vector machine (SVM), and k-nearest neighbors (KNN). On a pixel-by-pixel level, a classification accuracy of up to 95% could be achieved. The tentative identification of discriminative tryptic peptide signatures revealed proteins that are involved in the epigenetic regulation of the genome and tumor microenvironment. Despite their histomorphological similarities, mass spectrometry imaging represents an efficient and reliable approach for the distinction of PDAC from CC, offering a promising complementary or alternative approach to the existing tools used in diagnostics such as immunohistochemistry.

Identifiants

pubmed: 35684402
pii: molecules27113464
doi: 10.3390/molecules27113464
pmc: PMC9182561
pii:
doi:

Substances chimiques

Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : 329628492

Références

Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Liver Int. 2019 May;39 Suppl 1:7-18
pubmed: 30882996
Pancreatology. 2010;10(4):429-33
pubmed: 20720444
Proteomics. 2014 Apr;14(7-8):965-72
pubmed: 24678008
Biology (Basel). 2021 Oct 12;10(10):
pubmed: 34681132
Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):257-63
pubmed: 22990105
Mol Imaging Biol. 2018 Dec;20(6):888-901
pubmed: 30167993
Hum Pathol. 2014 Feb;45(2):394-400
pubmed: 24439226
World J Gastroenterol. 2014 Jun 28;20(24):7864-77
pubmed: 24976723
Proteomics. 2008 Sep;8(18):3715-24
pubmed: 18712763
Hum Pathol. 2010 Sep;41(9):1310-9
pubmed: 20471664
Cancer Genet. 2018 Aug;224-225:21-28
pubmed: 29778232
Clin Lab Med. 2018 Jun;38(2):367-384
pubmed: 29776636
Arch Pathol Lab Med. 2015 Jul;139(7):848-57
pubmed: 26125425
Pathol Oncol Res. 2021 Apr 20;27:1609756
pubmed: 34257615
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Anal Chem. 2021 Aug 3;93(30):10584-10592
pubmed: 34297545
Virchows Arch. 2017 May;470(5):537-543
pubmed: 28357490
Proteomics Clin Appl. 2019 Jan;13(1):e1800029
pubmed: 30408343
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
Oncogene. 2021 Mar;40(11):2065-2080
pubmed: 33627784
Nat Commun. 2021 Apr 20;12(1):2328
pubmed: 33879793
Nat Rev Cancer. 2010 Sep;10(9):639-46
pubmed: 20720571
Proteomics Clin Appl. 2019 Jan;13(1):e1800035
pubmed: 30035857
Mol Cell Proteomics. 2016 Mar;15(3):1072-82
pubmed: 26644413
J Am Coll Surg. 2017 Apr;224(4):406-413
pubmed: 28017812
J Gastrointest Surg. 2016 May;20(5):953-9
pubmed: 26956004
Mol Cell Proteomics. 2016 Oct;15(10):3081-3089
pubmed: 27473201
Proteomics Clin Appl. 2019 Jan;13(1):e1800046
pubmed: 30548962
Mod Pathol. 2016 Nov;29(11):1358-1369
pubmed: 27469329
Hum Pathol. 2012 Oct;43(10):1583-9
pubmed: 22406361
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):380-7
pubmed: 24532422
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19609-19618
pubmed: 31484774
Nat Rev Dis Primers. 2021 Sep 9;7(1):65
pubmed: 34504109

Auteurs

Christine Bollwein (C)

Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.

Juliana Pereira Lopes Gonҫalves (JPL)

Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.

Kirsten Utpatel (K)

Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Wilko Weichert (W)

Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.

Kristina Schwamborn (K)

Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH